Insulin-like growth factor-1 gene therapy - Valentis

Drug Profile

Insulin-like growth factor-1 gene therapy - Valentis

Alternative Names: IGF-1 gene therapy - Valentis; Somatomedin-1 gene therapy - Valentis

Latest Information Update: 31 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valentis
  • Class Antihyperglycaemics; Gene therapies; Growth factors
  • Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic neuropathies; Genitourinary disorders; Postmenopausal osteoporosis

Most Recent Events

  • 03 Feb 2003 A preclinical study has been added to the Genitourinary disorders pharmacodynamics section
  • 22 Jun 1999 The merged company of GeneMedicine and Megabios is now called Valentis
  • 29 Mar 1999 GeneMedicine has merged with Megabios
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top